Paclitaxel for AIDS-associated Kaposi’s sarcoma

Abstract

Treatment options are limited for patients with advanced acquired immunodeficiency syndrome-related Kaposi’s sarcoma (AIDS-KS). The management of early stage cutaneous AIDS-KS has been revolutionized by the introduction of highly active antiretroviral therapy and for most patients highly active antiretroviral therapy alone will control early stage AIDS-KS. However, patients with advanced stage Kaposi’s sarcoma with visceral disease, tumor-associated edema or extensive oral disease require systemic chemotherapy in addition to antiretrovirals. The standard first-line therapy for these affected individuals is a liposomal anthracycline, and response rates of around 70% are usually achieved. For patients with refractory or recurrent AIDS-KS, treatment algorithms are less well defined. The use of paclitaxel in these circumstances is reviewed.

Keywords::

• AIDS
• HIV
• Kaposi’s sarcoma
• paclitaxel